Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New PR Announcing Initiation of Basket Trial

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on May 10, 2022 10:37am

163 Views

Post# 34670260

RE:RE:RE:RE:New PR Announcing Initiation of Basket Trial

I agree.... It says nothing about the future....I suppose that risks of adverse effects increase as the number of cycles increase...

qwerty22 wrote:

I think you (and Palinc) need to be careful when thinking about DLT. It doesn't mean no AEs. It means no AEs IN THE FIRST CYCLE. It's a definition used in the hunt for the MTD and RP2D and that's all. It may be indicative of a good safety profile but it's a very limited number of doses and not enough to really make that call. When Christian says no DLTs in these six patients he's saying nothing about their 2nd dose or 3rd (if they received them). I don't want to suggest they are hiding stuff here. They are only talking about DLTs(rather than all the AEs) because all they are interested in sharing with us is the dose going forward and the start of the expansion phase. Once you make that decision then it's just DLTs.

Wino115 wrote: At least we know it's done, no issues, and on to the more interesting and informing part of the basket trial. I'll take that.

1. "..firmly believe" the cell entry is an advantage, so they may have (very speculative) seen data around chemo not going anywhere, thus it must be into the cell.

2. Continue to develop other anti-cancer agents, so maybe they're further along...please tell us!

3. "NO DLTs" - We thought this would be the case, but it is very positive to start your first in human efficacy trials with a NO DLT label. We know some of the ADCs had issues that delayed them and required counter-medications to control some of the DLTs. It's at least a good starting point.

Let the Trials Begin!

Hopefully someone at the meeting in a few hours can tell us more.

palinc2000 wrote:
The only new news even though it was expected is that the last 6 patients did not have any serious adverse effects...The rest of the PR is almost old news

mikeq113 wrote:

Big fat nothingburger of a PR initiating the basket trial. If they're confident - they're really not showing it to the greater shareholder base or the market.

https://www.theratech.com/news-releases/news-release-details/theratechnologies-initiates-basket-portion-th1902-first-human